Increased lipid peroxidation in Down's syndrome mouse models

Journal of Neurochemistry

Volumn 110, Issue 6, 2009, Pages 1965-1976

  Ishihara, Keiichi ^a   Amano, Kenji ^a   Takaki, Eiichi ^a   Ebrahim, Abdul Shukkur ^a   Shimohata, Atsushi ^a   Shibazaki, Noriko ^a   Inoue, Ikuyo ^a   Takaki, Mayuko ^b   Ueda, Yuto ^b   Sago, Haruhiko ^c   Epstein, Charles J ^d   Yamakawa, Kazuhiro ^a  

^a RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

13 hydroperoxy 9Z,11E octadecadienoic acid; 4 hydroxy 2 nonenal; Animal models; Down's syndrome; Lipid peroxidation; Proteomics

Indexed keywords

13 HYDROPEROXY OCTADECADIENOIC ACID; 4 HYDROXYNONENAL; ADENOSINE TRIPHOSPHATE; ESSENTIAL FATTY ACID; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOSKELETON; DOWN SYNDROME; ELECTRON SPIN RESONANCE; FEMALE; FUNCTIONAL DISEASE; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; TRISOMY;

AGE FACTORS; ALDEHYDES; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LINOLEIC ACIDS; LIPID PEROXIDATION; LIPID PEROXIDES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRODIALYSIS; REACTIVE OXYGEN SPECIES; TRISOMY;

ANIMALIA;

EID: 69949164039     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06294.x     Document Type: Article

References (47)

1. Amano K., Sago H., Uchikawa C., Suzuki T., Kotliarova S. E., Nukina N., Epstein C. J. Yamakawa K. (2004) Dosage-dependent over-expression of genes in the trisomic region of Ts1Cje mouse model for Down syndrome. Hum. Mol. Genet. 13, 1333 1340.
2. Antonarakis S. E. Epstein C. J. (2006) The challenge of Down syndrome. Trends Mol. Med. 12, 473 479.
3. Belichenko P. V., Kleschevnikov A. M., Salehi A., Epstein C. J. Mobley W. C. (2007) Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. J. Comp. Neurol. 504, 329 345.
4. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248 254.
5. Brooksbank B. W. Balazs R. (1984) Superoxide dismutase, glutathione peroxidase and lipoperoxidation in Down's syndrome fetal brain. Brain Res. 318, 37 44.
6. Bush A. Beail N. (2004) Risk Factors for Dementia in People With Down Syndrome: Issues in Assessment and Diagnosis. Am. J. Ment. Retard. 109, 83 97.
7. Butterfield D. A., Reed T., Perluigi M., De Marco C., Coccia R., Cini C. Sultana R. (2006) Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 397, 170 173.
8. Cairns N. J., Uryu K., Bigio E. H. et al. (2004) α-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol. 108, 213 223.
9. Choksi K. B. Papaconstantinou J. (2008) Age-related alterations in oxidatively damaged proteins of mouse heart mitochondrial electron transport chain complexes. Free Radic. Biol. Med. 44, 1795 1805.
10. Dickson T. C., Chuckowree J. A., Chuah M. I., West A. K. Vickers J. C. (2005) α-Internexin immunoreactivity reflects variable neuronal vulnerability in Alzheimer's disease and supports the role of the beta-amyloid plaques in inducing neuronal injury. Neurobiol. Dis. 18, 286 295.
11. Ermak G., Morgan T. E. Davies K. J. (2001) Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J. Biol. Chem. 276, 38787 38794.
12. Esterbauer H., Schaur R. J. Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11, 81 128.
13. Fu Y. Ji L. L. (2003) Chronic ginseng consumption attenuates age-associated oxidative stress in rats. J. Nutr. 133, 3603 3609.
14. Galloway P. G., Mulvihill P. Perry G. (1992) Filaments of Lewy bodies contain insoluble cytoskeletal elements. Am. J. Pathol. 140, 809 822.
15. Gardiner K., Fortna A., Bechtel L. Davisson M. T. (2003) Mouse models of Down syndrome: how useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 318, 137 147.
16. Goldman J. E., Yen S. H., Chiu F. C. Peress N. S. (1983) Lewy bodies of Parkinson's disease contain neurofilament antigens. Science 221, 1082 1084.
17. Ishii T., Haga S. Tokutake S. (1979) Presence of neurofilament protein in Alzheimer's neurofibrillary tangles (ANT). An immunofluorescent study. Acta Neuropathol. 48, 105 112.
18. Kapphahn R. J., Giwa B. M., Berg K. M., Roehrich H., Feng X., Olsen T. W. Ferrington D. A. (2006) Retinal proteins modified by 4-hydroxynonenal: identification of molecular targets. Exp. Eye Res. 83, 165 175.
19. Kato Y., Mori Y., Makino Y., Morimitsu Y., Hiroi S., Ishikawa T. Osawa T. (1999) Formation of Nε-(hexanonyl)lysine in protein exposed to lipid hydroperoxide. A plausible marker for lipid hydroperoxide-derived protein modification. J. Biol. Chem. 274, 20406 20414.
20. LeBel C. P., Ischiropoulos H. Bondy S. C. (1992) Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 5, 227 231.
21. Lockrow J., Prakasam A., Huang P., Bimonte-Nelson H., Sambamurti K. Granholm A. C. (2009) Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model. Exp. Neurol. 216, 278 289.
22. Markesbery W. R. Lovell M. A. (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19, 33 36.
23. Neely M. D., Sidell K. R., Graham D. G. Montine T. J. (1999) The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin. J. Neurochem. 72, 2323 2333.
24. Nunomura A., Perry G., Pappolla M. A., Friedland R. P., Hirai K., Chiba S. Smith M. A. (2000) Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome. J. Neuropathol. Exp. Neurol. 59, 1011 1017.
25. Odetti P., Angelini G., Dapino D. et al. (1998) Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Commun. 243, 849 851.
26. Perluigi M., Fai Poon H., Hensley K., Pierce W. M., Klein J. B., Calabrese V., De Marco C. Butterfield D. A. (2005) Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice - a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 38, 960 968. (Pubitemid 40321087)
27. Porta S., Serra S. A., Huch M., Valverde M. A., Llorens F., Estivill X., Arbonés M. L. Martíl E. (2007) RCAN1 (DSCR1) increases neuronal susceptibility to oxidative stress: a potential pathogenic process in neurodegeneration. Hum. Mol. Genet. 16, 1039 1050.
28. Reed T., Perluigi M., Sultana R., Pierce W. M., Klein J. B., Turner D. M., Coccia R., Markesbery W. R. Butterfield D. A. (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol. Dis. 30, 107 120.
29. Richtsmeier J. T., Zumwalt A., Carlson E. J., Epstein C. J. Reeves R. H. (2002) Craniofacial phenotypes in segmentally trisomic mouse models for Down syndrome. Am. J. Med. Genet. 107, 317 324.
30. Sago H., Carlson E. J., Smith D. J., Kilbridge J., Rubin E. M., Mobley W. C., Epstein C. J. Huang T. T. (1998) Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc. Natl Acad. Sci. USA 95, 6256 6261.
31. Sayre L. M., Zelasko D. A., Harris P. L., Perry G., Salomon R. G. Smith M. A. (1997) 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68, 2092 2097.
32. Shukkur E. A., Shimohata A., Akagi T. et al. (2006) Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet. 15, 2752 2762.
33. Siarey R. J., Villar A. J., Epstein C. J. Galdzicki Z. (2005) Abnormal synaptic plasticity in the Ts1Cje segmental trisomy 16 mouse model of Down syndrome. Neuropharmacology, 49, 122 128.
34. Szweda L. I., Uchida K., Tsai L. Stadtman E. R. (1993) Inactivation of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Selective modification of an active-site lysine. J. Biol. Chem., 268, 3342 3347.
35. Takaki M., Ueda Y., Doi T., Nagatomo K., Murashima Y. L., Nakajima A. Kannan H. (2007) Age-dependent changes in the hippocampal antioxidant ability of EL mice. Neurosci. Res. 58, 336 338.
36. Uchida K. Stadtman E. R. (1993a) Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J. Biol. Chem. 268, 6388 6393.
37. Uchida K., Szweda L. I., Chae H. Z. Stadtman E. R. (1993b) Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc. Natl Acad. Sci. USA 90, 8742 8746.
38. Ueda Y., Yokoyama H., Tokumaru J., Doi T. Nakajima A. (2004) Kinetics of extracellular nitroxide radical and glutamate levels in the hippocampus of conscious rats: cautionary note to the application of nitroxide radical on clinical arena. Neurochem. Res. 29, 1695 1701.
39. Ueda Y., Doi T., Nagatomo K. Nakajima A. (2007) Protective role of pentobarbital pretreatment for NMDA-R activated lipid peroxidation is derived from the synergistic effect on endogenous anti-oxidant in the hippocampus of rats. Neurosci. Lett. 417, 46 49.
40. 16)65Dn and mouse chromosome 12. Mamm. Genome 16, 79 90.
41. Vogel P., Gabriel M., Goebel H. H. Dyck P. J. (1985) Hereditary motor sensory neuropathy type II with neurofilament accumulation: new finding or new disorder? Ann. Neurol. 17, 455 461.
42. Wang X., Phelan S. A., Forsman-Semb K., Taylor E. F., Petros C., Brown A., Lerner C. P. Paigen B. (2003) Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. J. Biol. Chem. 278, 25179 25190.
43. Williams T. I., Lynn B. C., Markesbery W. R. Lovell M. A. (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging 27, 1094 1099.
44. Wood Z. A., Schroder E., Robin Harris J. Poole L. B. (2003) Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28, 32 40.
45. Yamakawa K., Huo Y.-K., Haendel M. A., Hubert R., Chen X.-N., Lyons G. E. Korenberg J. R. (1998) DSCAM: a novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. Hum. Mol. Genet. 7, 227 237.
46. Yuan A., Rao M. V., Sasaki T. et al. (2006) α-internexin is structurally and functionally associated with the neurofilament triplet proteins in the mature CNS. J. Neurosci. 26, 10006 10019.
47. Zana M., Janka Z. Kálmán J. (2007) Oxidative stress: bridge between Down's syndrome and Alzheimer's disease. Neurobiol. Aging 28, 648 676.